What Is The Current and Historic Market Size Analysis Of The Veterinary Biologics Market?
The veterinary biologics market has seen considerable growth due to a variety of factors.
•In recent times, there has been robust growth in the size of the veterinary biologics market. The forecast suggests an upward trend from $12.67 billion in 2024 to $13.65 billion in 2025, registering a compound annual growth rate (CAGR) of 7.7%.
Factors contributing to this growth during the historical period include outbreaks of animal diseases, regulatory provisions and standards, the necessity for food safety, trade globalization, and the economic importance of livestock.
What Are The Predictions for The Veterinary Biologics Market Size In The Coming Years?
The veterinary biologics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for veterinary biologics is slated to experience robust expansion in the forthcoming years, escalating to $18.38 billion by 2029 with a compound annual growth rate (CAGR) of 7.7%.
This surge during the forecast period is attributed to factors like the outbreak of new infectious diseases, shifts in climate and disease patterns, precision livestock farming, the adoption of the one health approach and a growing trend of pet ownership. During the forecast period, key trends that can be observed include the implementation of education and training programs, eco-friendly and sustainable biologics, the incorporation of digital health records, the rise in the use of biologics for companion animals, and the development of customized and targeted therapies.
Which Key Drivers Are Propelling The Veterinary Biologics Market's Growth?
The veterinary biologics market is expected to flourish owing to the increasing instances of animal diseases. These diseases or health disorders affect a range of animal species and their surge requires enhanced diagnostic and treatment methods. Veterinary biologics, employing immunological techniques, serve as effective means for managing these diseases. For instance, the European Center for Disease Prevention and Control, a Sweden-based European Union health agency, recorded in October 2022, a total of 2,467 avian flu outbreaks in poultry that affected 48 million birds, with 187 instances observed in captive birds. Moreover, in July 2022, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported annual deaths of 59,000 people due to rabies in over 150 nations, predominantly in Africa and Asia, constituting 95% of cases. Consequently, the escalating incidence of animal diseases contributes to the growth of the veterinary biologics market.
What Are The Key Segments Within The Global Veterinary Biologics Market?
The veterinary biologics market covered in this report is segmented –
1) By Product: Vaccines, Diagnostic Kits, Immunomodulators, Antiserums And Antibodies, Other Products
2) By Disease Type: Bluetongue, Foot And Mouth Disease, Brucellosis And Tuberculosis, Other Diseases
3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Other Distribution Channels
4) By Application: Production Animal, Companion Animal
Subsegments:
1) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, DNA Vaccines
2) By Diagnostic Kits: Rapid Tests, Elisa Kits, Pcr-Based Diagnostic Kits
3) By Immunomodulators: Cytokines, Adjuvants, Immunostimulants
4) By Antiserums And Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Hyperimmune Serums
5) By Other Products: Probiotics, Prebiotics, Growth Factors, Toxoids
Pre-Book The Veterinary Biologics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Veterinary Biologics Market?
Leading corporations in the veterinary biologics sector are concentrating on creating and innovating new biologics like vaccines in an effort to improve animal health and prevent diseases. Vaccines are substances that help the immune system to identify and combat particular pathogens, thereby preventing the spread of infectious diseases through acquired immunity. Take for instance, the US-based global animal healthcare company, Merck Animal Health, which in August 2024, introduced a trial autogenous vaccine with a target towards avian metapneumovirus (aMPV) type B. This vaccine, developed in partnership with Cambridge Technologies and sanctioned by the U.S. Department of Agriculture (USDA) for manufacture and sale, is meant to counteract serious respiratory problems caused by aMPV type B in poultry, a situation which has resulted in substantial financial losses since the end of 2023. The vaccine, made in a highly advanced facility in Minnesota, uses an oil and water emulsion formulation to reduce tissue reactions post-vaccination. This new development addresses an important market need since there were no commercially licensed vaccines available previously.
Who Are the Key Players in the Veterinary Biologics Market?
Major companies operating in the veterinary biologics market include:
• Bayer AG
• Eli Lilly & Company
• Evonik Industries AG
• Zoetis Inc.
• Merck Animal Health Inc.
• Boehringer Ingelheim Animal Health Inc.
• Elanco Animal Health
• IDEXX Laboratories Inc.
• Virbac SA
• Phibro Animal Health Corporation
• Vetoquinol
• Abaxis Inc.
• Bimeda Biologicals
• Ceva Sante Animale S.A.
• Heska Corporation
• Colorado Serum Company
• Hester Biosciences Limited
• INDICAL Bioscience GmbH
• Ambrx Biopharma Inc.
• Adamis Pharmaceuticals Corporation
• Intervet Inc.
• Hebei Veyong Animal Pharmaceutical Co. Ltd.
• FidoCure
• Biomet Biologics LLC
• CytoDyn Veterinary Medicine LLC
• KM Biologics
What are the Regional Insights into the Veterinary Biologics Market?
North America was the largest region in the veterinary biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
